Billiontoone (NASDAQ:BLLN) CTO David Tsao Sells 10,000 Shares

Billiontoone, Inc. (NASDAQ:BLLN) CTO David Tsao sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $100.00, for a total value of $1,000,000.00. Following the transaction, the chief technology officer owned 1,000 shares in the company, valued at $100,000. The trade was a 90.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Tsao also recently made the following trade(s):

• On Monday, August 10th, David Tsao sold 10,000 shares of Billiontoone stock. The stock was sold at an average price of $92.86, for a total value of $928,600.00.
• On Monday, June 15th, David Tsao sold 20,000 shares of Billiontoone stock. The stock was sold at an average price of $102.27, for a total value of $2,045,400.00.

Billiontoone Price Performance

Shares of NASDAQ BLLN traded down $1.07 during trading on Thursday, hitting $95.15. 670,193 shares of the company were exchanged, compared to its average volume of 841,632. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.69 and a quick ratio of 11.31. Billiontoone, Inc. has a 1 year low of $61.96 and a 1 year high of $150.44. The company has a market cap of $4.49 billion and a price-to-earnings ratio of 137.46. The firm’s fifty day moving average price is $115.34 and its 200 day moving average price is $95.29.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, meeting the consensus estimate of $0.15. The firm had revenue of $109.45 million during the quarter. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. On average, sell-side analysts expect that Billiontoone, Inc. will post 0.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on BLLN shares. JPMorgan Chase & Co. reduced their price target on Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research note on Thursday, August 6th. Weiss Ratings raised Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. BTIG Research dropped their target price on Billiontoone from $142.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Guggenheim initiated coverage on Billiontoone in a research report on Monday, June 29th. They set a “buy” rating and a $125.00 target price on the stock. Finally, Wall Street Zen lowered Billiontoone from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Billiontoone presently has an average rating of “Moderate Buy” and a consensus price target of $126.71.

Institutional Investors Weigh In On Billiontoone

Several large investors have recently added to or reduced their stakes in BLLN. Adams Street Partners LLC acquired a new stake in shares of Billiontoone in the 4th quarter worth about $140,063,000. Wasatch Advisors LP grew its stake in shares of Billiontoone by 40.2% in the 2nd quarter. Wasatch Advisors LP now owns 518,084 shares of the company’s stock worth $62,160,000 after purchasing an additional 148,446 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in Billiontoone in the fourth quarter worth approximately $39,717,000. JPMorgan Chase & Co. purchased a new stake in shares of Billiontoone during the fourth quarter valued at $32,078,000. Finally, Emerald Advisers LLC increased its stake in Billiontoone by 26.8% in the 1st quarter. Emerald Advisers LLC now owns 239,562 shares of the company’s stock worth $18,911,000 after purchasing an additional 50,613 shares in the last quarter.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.